Ira Berkower

2.3k total citations
45 papers, 1.9k citations indexed

About

Ira Berkower is a scholar working on Virology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Ira Berkower has authored 45 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Virology, 16 papers in Radiology, Nuclear Medicine and Imaging and 15 papers in Molecular Biology. Recurrent topics in Ira Berkower's work include HIV Research and Treatment (19 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and Virology and Viral Diseases (7 papers). Ira Berkower is often cited by papers focused on HIV Research and Treatment (19 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and Virology and Viral Diseases (7 papers). Ira Berkower collaborates with scholars based in United States, Hungary and United Kingdom. Ira Berkower's co-authors include Jerard Hurwitz, Jay A. Berzofsky, Jonathan Leis, Frank R.N. Gurd, G K Buckenmeyer, Yanling Jin, J A Berzofsky, Reed B. Wickner, Kemp B. Cease and L A Matis and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Ira Berkower

45 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ira Berkower United States 21 942 803 534 356 298 45 1.9k
Gordon Tribbick Australia 16 1.0k 1.1× 389 0.5× 595 1.1× 313 0.9× 120 0.4× 30 1.9k
Weizao Chen United States 26 1.0k 1.1× 734 0.9× 840 1.6× 184 0.5× 600 2.0× 59 2.1k
Jonathan Rothbard United Kingdom 11 816 0.9× 1.2k 1.4× 341 0.6× 292 0.8× 669 2.2× 13 2.1k
Marie‐France del Guercio United States 18 904 1.0× 1.3k 1.7× 363 0.7× 354 1.0× 346 1.2× 21 1.9k
S D Showalter United States 21 789 0.8× 610 0.8× 226 0.4× 655 1.8× 239 0.8× 45 1.9k
Yang Feng United States 28 1.0k 1.1× 702 0.9× 989 1.9× 355 1.0× 498 1.7× 58 2.5k
Jason P. Gardner United States 22 600 0.6× 734 0.9× 309 0.6× 537 1.5× 227 0.8× 33 2.1k
Richard Harrop United Kingdom 29 660 0.7× 1.1k 1.4× 223 0.4× 266 0.7× 127 0.4× 66 2.5k
Glenn Ishioka United States 24 844 0.9× 1.5k 1.8× 363 0.7× 591 1.7× 178 0.6× 45 2.3k
Raju K. Koduri United States 10 623 0.7× 680 0.8× 461 0.9× 252 0.7× 1.1k 3.7× 12 1.7k

Countries citing papers authored by Ira Berkower

Since Specialization
Citations

This map shows the geographic impact of Ira Berkower's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ira Berkower with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ira Berkower more than expected).

Fields of papers citing papers by Ira Berkower

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ira Berkower. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ira Berkower. The network helps show where Ira Berkower may publish in the future.

Co-authorship network of co-authors of Ira Berkower

This figure shows the co-authorship network connecting the top 25 collaborators of Ira Berkower. A scholar is included among the top collaborators of Ira Berkower based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ira Berkower. Ira Berkower is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosati, Margherita, Kate E. Broderick, Mark G. Lewis, et al.. (2020). Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques. PLoS ONE. 15(3). e0228163–e0228163. 3 indexed citations
3.
Valentin, Antonio, Jinyao Li, Margherita Rosati, et al.. (2015). Dose-dependent inhibition of Gag cellular immunity by Env in SIV/HIV DNA vaccinated macaques. Human Vaccines & Immunotherapeutics. 11(8). 2005–2011. 7 indexed citations
4.
Rosati, Margherita, Candido Alicea, Viraj Kulkarni, et al.. (2015). Recombinant rubella vectors elicit SIV Gag-specific T cell responses with cytotoxic potential in rhesus macaques. Vaccine. 33(18). 2167–2174. 7 indexed citations
6.
Berkower, Ira, et al.. (2012). Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers. Vaccine. 30(37). 5453–5458. 8 indexed citations
7.
Phogat, Sanjay, Krisha Svehla, Min Tang, et al.. (2008). Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology. 373(1). 72–84. 51 indexed citations
8.
9.
He, Yong, Jody Manischewitz, Clement A. Meseda, et al.. (2007). Antibodies to the A27 Protein of Vaccinia Virus Neutralize and Protect against Infection but Represent a Minor Component of Dryvax Vaccine–Induced Immunity. The Journal of Infectious Diseases. 196(7). 1026–1032. 27 indexed citations
10.
Berkower, Ira, et al.. (2004). Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120. Virology. 321(1). 75–86. 26 indexed citations
11.
Bašta, Milan, Stefano Luccioli, Eric M. Billings, et al.. (2003). F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nature Medicine. 9(4). 431–438. 177 indexed citations
12.
Patterson, L. Jean, et al.. (2001). Formation of HIV-1 Envelope-Hepatitis B Core Antigen Hybrids with High Affinity for CD4. Biochemical and Biophysical Research Communications. 285(3). 639–643. 3 indexed citations
13.
Berkower, Ira, et al.. (1998). Genetic Control of the Immune Response to HIV Type 1 Envelope Glycoprotein 120 in Mice: Effects of MHC and Transgenic Human CD4. AIDS Research and Human Retroviruses. 14(10). 893–900. 4 indexed citations
14.
Berkower, Ira. (1996). The promise and pitfalls of monoclonal antibody therapeutics. Current Opinion in Biotechnology. 7(6). 622–628. 19 indexed citations
15.
Berkower, Ira, H Mostowski, Thomas Bull, & D B Murphy. (1996). CD4-IgG Binding Threshold for Inactivation of Human Immunodeficiency Virus Type 1. The Journal of Infectious Diseases. 173(4). 863–869. 5 indexed citations
16.
Berkower, Ira, et al.. (1995). Genetic control of the murine humoral response to distinct epitopes of hepatitis C virus core protein. Journal of Viral Hepatitis. 2(1). 9–17. 9 indexed citations
17.
Reeves, J P, et al.. (1991). Anti-Leu3a Induces Combining Site-Related Anti-idiotypic Antibody Without Inducing Anti-HTV Activity. AIDS Research and Human Retroviruses. 7(1). 55–63. 6 indexed citations
18.
Berkower, Ira, et al.. (1989). Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation.. The Journal of Experimental Medicine. 170(5). 1681–1695. 49 indexed citations
20.
Berzofsky, Jay A., Kemp B. Cease, James Cornette, et al.. (1987). Protein Antigenic Structures Recognized by T Cells; Potential Applications to Vaccine Design. Immunological Reviews. 98(1). 9–52. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026